The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
Stock symbol 6502 not yet supported on Stock Buzz.

 Spectrum Pharmaceuticals Inc.  (SPPI) Trade Now »     Rate SPPI  -  Discuss SPPI  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
78.0%
Top:
100.0%
Rate SPPI:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

SPPI: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Bullish on SPPI ... Graphic_rating_buy SPPI
0_vader
77%
 +206.79%
in 384 days
(closed on 11/19/09)

SPPI just signed an exclusive collaboration agreement with Allergan, Inc. for the development and comercialization of aqaziuoine.  They will receive $41.5 million at closing and up to $304 million in milestone payments.  When they receive the $41.5 million they should have over $90 million in cash which should be almost $2.85 per share in cash. 

Also, they should be filing a supplemental NDA with the FDA  for their FUSILEV drug for colorectal cancer by the end of October 2008.

By  Darth Vader   (+1.23%  risk: conservative)  10/30/08 Comment


Neutral on SPPI ... SPPI
N/A
 +0.68%
in 5 days
(closed on 10/21/09)
 News of SPPI's  drug delay is digesting.  The stock should begin to increase again soon.  A third  of three  catalysts is up for revue in the coming months and sales from the first should start to help the bottom line.  All shareholders waist 2 in  for the FDA outcome for catalyst 2 in the coming months.
By  robert haag   (-6.32%  risk: conservative)  10/16/09 Comment


Bullish on SPPI ... Graphic_rating_buy SPPI
N/A
 -25.67%
in 58 days
I am a recruiter for them. We are EXPANDING THEIR SALESFORCE FOR FIRST LINE ZEVALIN < AND COLON CANCER SALES OF FUSILEV.
By  drugrecruiter   (-25.67%  risk: conservative)  09/25/09 Comment


RECENT NEWS Graphic_rating_buy SPPI
N/A
 -34.52%
in 73 days
spectrum Pharma tgt raised to $10 at Rodman & Renshaw following FDA approval for the expanded label of Zevalin Rodman & Renshaw raise their SPPI tgt to $10 from $8 following the FDA approval for an expanded label of Zevalin, which treats the previously untreated follicular non-Hodgkin's Lymphoma. With the label expansion, the treatable population expands from 6,000 to potentially 43,000 patients annually, in the firm's opinion.
By  Olof Thomas   (-4.32%  risk: conservative)  09/10/09 Comment


Techical Analysis Graphic_rating_buy SPPI
N/A
 -13.69%
in 1 day
(closed on 09/09/09)
SPPI- a commercial-stage biotechnology company with a primary focus in oncology. Expecting some FDA approval news October 8th that should send this stock flying!
By  Olof Thomas   (-4.32%  risk: conservative)  09/08/09 Comment




From the Blogosphere

Spectrum Pharma: Zevalin Sales Ramp Up

<font>On November 13, Spectrum Pharmaceuticals (SPPI) reported some positive Q3 results. Sales of their non-Hodgkin’s lymphoma (NHL) drug, Zevalin®, which made up more than half of the revenue generated during the quarter, continue to improve significantly.</font>

<><font>Over the past several months, many have argued that a Zevalin comeback was impossible. The drug has been ignored by doctors for several years. For this reason, many argue it’ll never sell today. I will not deny it, changing previously held beliefs and perceptions isn't always easy. Without question, the Zevalin turnaroun...
By  trackseekingalpha   (-11.47%  risk: aggressive)  11/22/09 Comment


Spectrum Pharma: CMS Rules in Favor of Zevalin

Spectrum Pharmaceuticals (SPPI) just announced that the Centers for Medicare and Medicade Services (CMS) ruled in favor of the company's radio-immunotherapy Zevalin®. Zevalin is now approved as a first-line treatment for patients with non-Hodgkin's lymphoma (NHL).

This is good news for SPPI as Zevalin will now be reimbursed at an average sales price (ASP) of most other cancer drugs. As I understand it, this ruling means that Zevain should now be reimbursed at a price +5% to +6% from its current price. It should be noted that the new price will be effective as of January 1, 2010.
By  trackseekingalpha   (-11.47%  risk: aggressive)  11/03/09 Comment


Spectrum Pharma: Zevalin Has Blockbuster Potential

A number of positive peer-reviews evaluating Spectrum Pharmaceuticals (SPPI) radio-immunotherapy (RIT), Zevalin® were published this month. The conclusions drawn in these reviews were made from unbiased medical professionals, and indicate that the prospects for Zevalin may be greater than I originally estimated back on <font>June 12</font>.

Based on the feedback received from a doctor whose opinion I value, I now believe Zevalin has blockbuster potential. In general, blockbuster drugs typically generate annual revenue of $1 billion or greater.
By  trackseekingalpha   (-11.47%  risk: aggressive)  10/25/09 Comment


Spectrum Pharma (SPPI) drops on cancer drug setback

Filed under: Major movement, Bad news, Options, Technical Analysis

SPPI logoSpectrum Pharmaceutical (NASDAQ: SPPI - option chain) stock is trading lower today after the company received a Complete Response letter from the FDA regarding FUSILEV, its treatment for advanced metastatic colorectal cancer. The FDA said the company did not demonstrate that FUSILEV is non-inferior to leucovorin in its supplemental New Drug Application. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on SPPI.

This morning, SPPI opened at $4.98....
By  Brent Archer   (-61.95%  risk: moderate)  10/09/09 Comment


Spectrum Pharmaceuticals: Undervalued and (Now) Oversold

<font>ROUND ONE</font>

<font>During the last pullback, Spectrum Pharmaceuticals (SPPI)</font><font> began to sell-off on June 30 after shares of the company had reached the first new multi-year high since July 2007. On June 30, SPPI topped at $8.15 and closed at $7.65.</font>
By  trackseekingalpha   (-11.47%  risk: aggressive)  09/24/09 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.25% 378
2 Gerald Greene 18.14 +70.10% 208
3 stockmarketfunding.com 17.66 +25.70% 55
4 akiralegrand 13.47 +14.32% 61
5 anup2104 12.13 +75.30% 38


POPULAR STOCKS
Symbol Company Name Sentiment
DELL Dell Inc
T AT&T Inc
ETFC E*Trade Financial Corp
MSFT Microsoft Corp
JNJ Johnson & Johnson
SIRI Sirius Satellite Radio Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on SPPI

Visit streetinsider.com


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About Spectrum Pharmaceuticals Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch